EXACT Sciences — Investor Day (June 2023)
127 slides from EXACT Sciences's investor day presentation, Jun 21, 2023
Slide 1: We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment
We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment. June 21, 2023 EXACT SCIENCES
Slide 2: Safe harbor and non-GAAP disclosures
Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are sub
Slide 3: Today's agenda
Today’s agenda 10:00 am Welcome and opening Kevin 10:20 am Invest in world-class talent Sarah 10:25 am Tests that impact decisions Jorge, Jake, Brian Kevin Conroy Sarah Condella CHAIRMAN AND CEO EVP, HUMAN RESOURCES 11:10 am Generate rock-solid evidence Jorge 11:25 am Increase access & drive adoptio
Slide 4: EXACT SCIENCES
EXACT SCIENCES 4 EXACT SCIENCES 4
Slide 5: We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment
We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment. Kevin Conroy Chairman and CEO EXACT SCIENCES 5
Slide 6: Our core values are embedded in everything we do
Our core values are embedded in everything we do MAY 2023-MAY 2024 USA Innovation Quality Teamwork Integrity Accountability EXACT SCIENCES 6
Slide 7: Leadership expectations and behaviors
LEADERSHIP Seeks and acts One team Takes personal Acts like an EXPECTATIONS on feedback approach – puts accountability to owner – makes team ahead of deliver quality decisions and self results moves AND quickly BEHAVIORS HUMILITY WILL Celebrates Relentlessly success and Acts on Listens, thinks, focu
Slide 8: Invest in world-class talent dedicated to fighting cancer
Invest in world-class talent dedicated to fighting cancer Drive profitable Offer tests that revenue impact decision-making Provide a seamless Generate experience for rock-solid clinical customers evidence Increase access & drive adoption EXACT SCIENCES 8
Slide 9: Progress towards eradicating cancer
Progress towards eradicating cancer TOP-LINE VISIONARY BLUE-C RESULTS COLLABORATIONS EXACT SCIENCES 9
Slide 10: A new standard in next-generation non-invasive screening
A new standard in next-generation non-invasive screening EXACT SCIENCES 10
Slide 11: DeeP-C vs BLUE-C performance
87% 91% specificity including non- specificity including non- advanced findings advanced findings 90% 93% specificity including specificity including no findings no findings 92% 94% DeeP-C BLUE-C next-generation cancer cancer sensitivity sensitivity 69% 75% high-grade dysplasia high-grade dysplasia
Slide 12: How we help detect cancer earlier and provide smarter answers at every step
How we help detect cancer earlier and provide smarter answers at every step Hereditary testing Screening & diagnosis MRD & recurrence expected 2023 multi-cancer liver, esophageal, & others Early-stage therapy Prognosis & prediction Includes tests in development, which are EXACT SCIENCES not availabl
Slide 13: EXACT SCIENCES
EXACT SCIENCES 13 13
Slide 14: Invest in world-class talent
Invest in world-class talent Sarah Condella EVP, Human Resources EXACT SCIENCES 14 14
Slide 15: Invest in world-class talent dedicated to fighting cancer
Invest in world-class talent dedicated to fighting cancer Drive profitable Offer tests that revenue impact decision-making Provide a seamless Generate experience for rock-solid clinical customers evidence Increase access & drive adoption EXACT SCIENCES 15
Slide 16: EXACT SCIENCES
EXACT SCIENCES 16
Slide 17: The driving force behind our flywheel is our team
The driving force behind our flywheel is our team 6,300+ teammates dedicated to defeating cancer 54% 40+ locations globally in 18 cities gender diversity 100% of teammates are shareholders Source: Exact Sciences internal data EXACT SCIENCES 17
Slide 18: Attract, develop, retain
ATTRACT DEVELOP RETAIN EXACT SCIENCES 18 18
Slide 19: Our magnetic, purpose-driven culture attracts the best talent
ATTRACT Our magnetic, purpose-driven culture attracts the best talent 23K+ 2017 2018 2019 2020 2021 2022 1Q23 AVERAGE # OF QUARTERLY JOB APPLICATIONS EXACT SCIENCES Source: Exact Sciences internal data 19
Slide 20: Creating a more sustainable, cancer-free world for future generations
ATTRACT ATTRACT AND HIRE Creating a more sustainable, cancer-free world for future generations EXACT SCIENCES 20
Slide 21: Developing and promoting career growth is key to our success
DEVELOP & GROW DEVELOP Developing and promoting career growth is key to our success 330K 2 in 5 80%+ annual teammates enrolled of teammates participate training hours in mentorship program in wellness program EXACT SCIENCES Source: Exact Sciences internal data 21 21
Slide 22: Fostering innovation through engagement
RETAIN Fostering innovation through engagement GREAT PLACE TO WORK RESULTS 82% MAY 2023-MAY 2024 USA Best Workplaces in BiopharmaTM 57% Typical company Best-in-State Employer EXACT SCIENCES Source: Exact Sciences internal data 22
Slide 23: Changing lives, together
Changing lives, together EXACT SCIENCES 23
Slide 24: Develop tests that impact decisions
Develop tests that impact decisions Jorge Garces Chief Science Officer EXACT SCIENCES 24 24
Slide 25: Invest in world-class talent dedicated to fighting cancer
Invest in world-class talent dedicated to fighting cancer Drive profitable Offer tests that revenue impact decision-making Provide a seamless Generate experience for rock-solid clinical customers evidence Increase access & drive adoption EXACT SCIENCES 25
Slide 26: Broad scientific capabilities & leadership
Broad scientific capabilities & leadership OUR CAPACITY OUR TEAM 100K+ 285 square feet of operational scientists R&D lab space 4 110 PhDs in R&D R&D centers globally EXACT SCIENCES Source: Exact Sciences internal data 26
Slide 27: Methodical approach to product and evidence development
Methodical approach to product and evidence development Research & Adoption & Approval development access Sample & data Analytical Clinical performance Clinical Real-world collection performance & safety benefit vs. risk benefit vs. risk discovery, evaluation, sensitivity, specificity, sensitivity,
Slide 28: Multi-omics is the answer
Multi-omics is the answer Genomics Transcriptomics Proteomics (DNA) (RNA) (Proteins) Madison, WI San Diego, CA Madison, WI San Diego, CA Munich, Germany Boston, MA EXACT SCIENCES 28
Slide 29: Methylation
Methylation Unmatched marker discovery capabilities Sample acquisition Lung Breast Whole methylome Liver Ovary sequencing 500 Stomach Lymphoma methylation markers Marker selection validated across Colon Uterus Bile duct Cervix Marker refinement 16 of the Esophagus Melanoma deadliest cancers Marker t
Slide 30: Markers with greatest signal to noise
Methylation Unmatched marker discovery capabilities Discover markers in tissue Validate in blood, stool, other Marker selection process Dataset Healthy controls Ovarian cancers Learning Independent Markers with greatest signal to noise dataset test set Markers with Greatest Signal to Noise 5-fold cr
Slide 31: Mutations
Mutations Unmatched marker discovery capabilities EXACT SCIENCES 31
Slide 32: Proteins
Proteins Unmatched marker discovery capabilities Thousands 1 of proteins and phosphopeptides cancer sample Assay Platform Protein Discovery Platform Sample preparation Liquid chromatography Spectra interpretation Data analysis Mass spectrometry Protein quantification EXACT SCIENCES Source: Exact Sci
Slide 33: Sequencing power for all applications with 60 platforms
Sequencing power for all Expertise across technologies applications with 60 platforms with an automated platform 247K 26K 2.6K exomes transcriptomes genomes sequenced sequenced sequenced SANGER HIGH-THROUGHPUT NGS PRODUCTION-SCALE NGS SEQUENCING EXACT SCIENCES Source: Exact Sciences internal data 33
Slide 34: SaferSeqS & RealSeqS
SaferSeqS & RealSeqS Expertise across technologies with an automated platform Safer Sequencing System & Repetitive Element AneupLoidy Sequencing System Exact Sciences maintains exclusive rights Detects variants at frequencies below 1 in 100K DNA molecules Reduces the error rate of existing PCR-based
Slide 35: TELQAS Chemistry
TELQAS Chemistry TM Expertise across technologies with an automated platform Target Enrichment Long probe Quantitative Amplified Signal Developed and owned by Exact Sciences Single copy detection Faster time to result LQAS 120 LQAS 100 10K 100 Multiplex PCR 80 RFU 60 TaqMan 10K 40 Limited sample 12
Slide 36: Exact Sciences is technology agnostic
Exact Sciences is Expertise across technologies technology agnostic with an automated platform 300 130 60 Hamilton liquid handlers Real-time ABI 7500 systems Sequencers EXACT SCIENCES Source: Exact Sciences internal data 36
Slide 37: LBgard
LBgard ® Expertise across technologies with an automated platform Proprietary technology increases yield and decreases contamination 109% 52% increase in plasma recovery yield decrease in gDNA contamination Plastic external tube Glass internal coating Plasma Cell-free DNA (cfDNA) Proteins Exosomes B
Slide 38: Proficiency optimizing comprehensive algorithms
Proficiency optimizing comprehensive algorithms training cross validation independent sets validation sets test sets artificial neural networks 70 multi-marker approach proprietary chemistry person bioinformatics team machine learning classifier EXACT SCIENCES 38 38
Slide 39: Strong intellectual property portfolio protects unique advantages
Strong intellectual property portfolio protects unique advantages 900+ 400+ patents issued worldwide patent applications filed EXACT SCIENCES Source: Exact Sciences internal data 39
Slide 40: Offer tests that impact decisions
Offer tests that impact decisions Jake Orville General Manager, Screening EXACT SCIENCES 40
Slide 41: How we help detect cancer earlier and provide smarter answers at every step
How we help detect cancer earlier and provide smarter answers at every step Hereditary testing Screening & diagnosis MRD & recurrence expected 2023 multi-cancer liver, esophageal, & others Early-stage therapy Prognosis & prediction Includes tests in development, which are EXACT SCIENCES 41 not avail
Slide 42: Providing the best screening tests to help prevent and detect cancer earlier
Providing the best screening tests to help prevent and detect cancer earlier Hereditary Therapy selection testing & monitoring Screening & diagnosis MRD & recurrence expected 2023 multi-cancer liver, esophageal, & others Early-stage therapy Prognosis & prediction Includes tests in development, which
Slide 43: Colorectal cancer: 60M unscreened Americans
COLORECTAL CANCER Diagnosed in stage IV 60M unscreened Americans ages 45-85 1 out of 10 survive Source: Fisher D et al., ASCO Gastrointestinal Cancers Symposium (2022); Exact Sciences estimates based on 51% screening rate for ages 50-85 and 10-15% screening rate for ages 45-49; Siegel RL et al., Can
Slide 44: Colorectal cancer: diagnosed in stages I & II
COLORECTAL CANCER 94% 91% Diagnosed in stages I & II cancer sensitivity specificity 92% 87% Easy to use No sedation Non-invasive No time off work 9 out of 10 survive 24/7 support No preparation Source: Imperiale TF et al., N Engl J Med (2014); Siegel RL et al., Cancer Statistics (2022); Exact Scienc
Slide 45: Colorectal cancer timeline
COLORECTAL CANCER COLORECTAL CANCER FDA USPSTF approval guidelines Aug Jun Completed DeeP-C Medicare HEDIS 1M people 10M people Expected enrollment NCD measures screened screened USPSTF Nov Oct Oct Feb Nov update 2012 2014 2016 2018 2020 2022 2024 2026 2028 2013 2015 2017 2019 2021 2023 2025 2027 30
Slide 46: 35M+ expected people screened by 2027
COLORECTAL CANCER 35M+ expected people screened by 2027 expected people screened by 2027 EXACT SCIENCES 46
Slide 47: A test and services
COLORECTAL CANCER A test and Options services and services EXACT SCIENCES 47
Slide 48: Multi-cancer: diagnosed in stage IV
MULTI-CANCER Diagnosed in stage IV 70% of cancers have no SCREENING OPTIONS 2 out of 10 survive Source: United States Preventive Services Task Force. A and B recommendations (2022); Siegel RL et al., A. Cancer Statistics (2021); Siegel DA et al., JAMA Oncol. (2021); Richards TB et al. Morb Mortal Wk
Slide 49: Multi-cancer: 135M Americans ages 45-85
MULTI-CANCER Diagnosed in stage I 135M Americans ages 45-85 8 out of 10 survive Source: U.S. Census data; American Cancer Society statistics on average 5-year relative survival rates for 19 leading cancers EXACT SCIENCES 49
Slide 50: DETECT-A
MULTI-CANCER Adding mutation to methylation improves accuracy The first prospective study 35% improvement in early-stage sensitivity 10K asymptomatic people DETECT-A 29% 39% Doubled cancers found compared to SOC alone 2/3 were earlier stages 3 marker 4 marker classes classes Case-control data presen
Slide 51: Refine clinical implementation practices
MULTI-CANCER Refine clinical implementation practices Generate real-world evidence Optimize ordering workflow EXACT SCIENCES 51
Slide 52: Exact Sciences acquires Thrive
BUILT ON THE EXACT SCIENCES TO CREATE FOUNDATION CREATED BY ACQUIRES THRIVE TM EXACT SCIENCES 52
Slide 53: How we help detect cancer earlier and provide smarter answers at every step
How we help detect cancer earlier and provide smarter answers at every step Hereditary testing Screening & diagnosis MRD & recurrence expected 2023 liver, esophageal, & others Early-stage therapy Prognosis & prediction Includes tests in development, which are EXACT SCIENCES 53 not available for sale
Slide 54: Offer tests that impact decisions
Offer tests that impact decisions Brian Baranick General Manager, Precision Oncology EXACT SCIENCES 54
Slide 55: Enabling personalized medicine through our Precision Oncology portfolio
Enabling personalized medicine through our Precision Oncology portfolio Hereditary testing Screening & diagnosis MRD & recurrence expected 2023 liver, esophageal, & others Early-stage therapy Prognosis & prediction Includes tests in development, which are EXACT SCIENCES 55 not available for sale or
Slide 56: Katie Couric video
KATIE COURIC VIDEO https://exactsciences.app.box.com/s/z od7dxyokb5iyeanxe4t2rrn841nnkoi 56 EXACT SCIENCES 56
Slide 57: Oncotype DX established a new standard in personalized cancer care
Oncotype DX established a new standard in personalized cancer care ~1.2M ~1M $400M+ 80%+ cumulative U.S. U.S. patients spared U.S. U.S. market patients tested unnecessary chemotherapy revenue penetration EXACT SCIENCES Source: Sparano et al., N Engl J Med (2018); Geyer et al., NPJ Breast Cancer (201
Slide 58: Oncotype DX is supported by unmatched evidence and all major guidelines
Oncotype DX is supported by unmatched evidence and all major guidelines 100K+ patients with published prospective outcomes TAILORx RxPONDER 10K women, 12 years 5K women, 5 years ASCO® NCCN® ESMO ST. GALLEN NICE Range: 0-100 EXACT SCIENCES Source: Sparano et al., N Engl J Med (2018); Geyer et al., NP
Slide 59: Oncotype DX provides an international Precision Oncology footprint
Oncotype DX provides an international Precision Oncology footprint 110 120 sales team country members presence Solidify standard of care in established markets + Increase adoption in growing markets Launch in new markets EXACT SCIENCES Source: Exact Sciences internal data 59
Slide 60: Our platform provides unique advantages in Precision Oncology
Our platform provides unique advantages in Precision Oncology Commercial channel EMR platform Relationships with 90%+ of oncologists Seamless ordering and resulting Tissue access Patient compliance engine ~200K samples each year Facilitates recurring testing Global footprint Lab operations excellenc
Slide 61: Hybrid capture technology
Hybrid capture technology Targets and captures specific DNA fragments Proprietary detection algorithm Operationally reliable Superior LBgard® collection tubes EXACT SCIENCES 61
Slide 62: Whole genome technology
Whole genome technology Expanded breadth of mutations Attractive cost profile EXACT SCIENCES 62
Slide 63: Universal platform supports entrance into colon cancer and expansion soon after
Universal platform supports entrance into colon cancer and expansion soon after COLON BREAST ADDITIONAL CANCER CANCER CANCER TYPES Second largest opportunity Largest opportunity Universal MRD platform Established evidence & Demonstrate clinical utility Tumor-informed and reimbursement through partne
Slide 64: Providing ultra-comprehensive genomic profiling, including DNA and RNA
Providing ultra-comprehensive genomic profiling, including DNA and RNA 20,000 genes DNA (tumor + inherited) ~325 20,000+ targets RNA ~50 Protein Other tests OncoExTra EXACT SCIENCES Source: Exact Sciences internal data 64
Slide 65: Selena: hereditary cancer
HEREDITARY CANCER + - + - 48 MRD BASELINE RS result + - MRD SURVEILLANCE + - Selena, MRD SURVEILLANCE + - a colorectal cancer patient MRD SURVEILLANCE + - 65 EXACT SCIENCES Illustrative example, not a real patient
Slide 66: Selena: screening
SCREENING + - + - 48 MRD BASELINE RS result + - + - MRD SURVEILLANCE Selena, MRD SURVEILLANCE + - a colorectal cancer patient MRD SURVEILLANCE + - 66 EXACT SCIENCES Illustrative example, not a real patient
Slide 67: Selena: early-stage cancer
EARLY-STAGE CANCER + - + - 48 MRD BASELINE RS result + - MRD SURVEILLANCE + - Selena, MRD SURVEILLANCE + - a colorectal cancer patient MRD SURVEILLANCE + - 67 EXACT SCIENCES Illustrative example, not a real patient
Slide 68: Selena: recurrence testing
RECURRENCE TESTING + - + - 48 MRD BASELINE RS result + - MRD SURVEILLANCE + - Selena, MRD SURVEILLANCE + - a colorectal cancer patient MRD SURVEILLANCE + - 68 EXACT SCIENCES Illustrative example, not a real patient
Slide 69: Selena: relapse
RELAPSE + - + - 48 MRD BASELINE RS result + - MRD SURVEILLANCE + - Selena, MRD SURVEILLANCE + - a colorectal cancer patient MRD SURVEILLANCE + - 69 EXACT SCIENCES Illustrative example, not a real patient
Slide 70: Generate rock-solid evidence
Generate rock- solid evidence Jorge Garces Chief Science Officer EXACT SCIENCES 70 70
Slide 71: Invest in world-class talent dedicated to fighting cancer
Invest in world-class talent dedicated to fighting cancer Drive profitable Offer tests that revenue impact decision-making Provide a seamless Generate experience for rock-solid clinical customers evidence Increase access & drive adoption EXACT SCIENCES 71
Slide 72: Generating evidence "the Exact way"
Generating evidence “the Exact way” Clinical Real-world Modeling trials definitively evidence and studies establishing test long-term outcomes demonstrating performance supporting test use population impact EXACT SCIENCES 72 72
Slide 73: Exact Sciences conducts studies that make a difference over the long term
Exact Sciences conducts studies that make a difference over the long term TAILOR-X 10K 6 RxPONDER 5K DeeP-C 10K NEJM publications DETECT-A 10K BLUE-C 20K Source: Sparano JA et al., N Engl J Med (2018); Kalinsky K et al., N Engl J Med (2021); Imperiale TF et al., N Engl J Med (2014); Paik S et al., N
Slide 74: We have access to more than 1.1M high-quality samples
We have access to more than 1.1M high-quality samples Aliquots in storage by sample type 439K 100+ Clinical Affairs team members 271K 275+ completed/ongoing clinical studies 186K 292K+ 116K 69K cumulative people enrolled 10K 9K 1K Plasma Stool Buffy coat Serum Tissue Cell pellet Blood Urine EXACT SC
Slide 75: BLUE-C
CLINICAL TRIALS BLUE-C 94% cancer Category, n (%) BLUE-C (n=20,208) DeeP-C (n=9,989) sensitivity Colorectal cancer 98 (0.48) 65 (0.65) next-generation Advanced pre- 2,146 (10.6) 757 (7.6) cancerous lesions Non-advanced 6,983 (34.6) 2,893 (29.0) 91% adenomas specificity including non- Negative 10,981
Slide 76: DETECT-A real-world evidence
REAL-WORLD EVIDENCE DETECT-A 100% 86% <1% of early-stage diagnosed and of surgically-treated of false-positive results treated patients still living patients in remission developed cancer annually cancer free over 4 years EXACT SCIENCES Source: Buchannan A et al., ASCO (2023); Lennon A et al., ASCO
Slide 77: SEER data
REAL-WORLD EVIDENCE SEER data 90K patients with invasive breast cancer Confirmed Oncotype DX was prognostic for 9 years breast cancer-specific mortality of follow up EXACT SCIENCES 77 Source: Geyer C et al., ASCO abstract (2023)
Slide 78: Modeling studies
MODELING STUDIES 100+ 40K+ 21K health economic studies scenarios lines of code in one in the last 3 years simulated colorectal cancer model EXACT SCIENCES Source: Exact Sciences internal data 78
Slide 79: Cologuard and Cancerguard
es, cologuard® EXACT SCIENCES aw cancerguard 79
Slide 80: Increase access and drive adoption
Increase access and drive adoption Everett Cunningham Chief Commercial Officer EXACT SCIENCES 80 80
Slide 81: Invest in world-class talent dedicated to fighting cancer
Invest in world-class talent dedicated to fighting cancer Drive profitable Offer tests that revenue impact decision-making Provide a seamless Generate experience for rock-solid clinical customers evidence Increase access & drive adoption EXACT SCIENCES 81
Slide 82: 1,200 person commercial organization
1,200 1,000 person commercial person field team organization Primary care Oncology Field Health Provider Medical Women’s team technology marketing geneticists health Surgeons Health Consumer Market Gastro- systems marketing access enterology International oncology Source: Exact Sciences internal dat
Slide 83: The most powerful commercial engine in diagnostics
The most powerful commercial engine in diagnostics PATIENTS HEALTH CARE HEALTH PAYERS PHARMA PROFESSIONALS SYSTEMS 85% 370K 275 780 60 brand cumulative providers electronic in-network biopharma awareness have ordered connections agreements partnerships EXACT SCIENCES Source: Exact Sciences internal
Slide 84: Deploying an all-encompassing sales and marketing strategy
Deploying an all-encompassing sales and marketing strategy Educating Health systems Surround health care and payer sound professionals relationships marketing EXACT SCIENCES 84 84
Slide 85: 1.6M+ field calls each year
EDUCATING HEALTH CARE PROFESSIONALS 1.6M+ FIELD CALLS EACH YEAR EXACT SCIENCES Source: Exact Sciences internal data 85 85
Slide 86: Data-driven insights promote agility and consistency
EDUCATING HEALTH CARE Educating PROFESSIONALS Data-driven insights promote health care agility and consistency professionals EXACT SCIENCES 86
Slide 87: Educating health care professionals
EDUCATING HEALTH CARE PROFESSIONALS EXACT SCIENCES 87
Slide 88: Health technology solutions
HEALTH SYSTEM & PAYER RELATIONSHIPS 85 strategic account managers Targets 400 largest U.S. health systems Health technology 60 solutions oncology centers and integrated delivery networks EXACT SCIENCES 88 88 Source: Exact Sciences internal data
Slide 89: Cologuard ordering through health systems
HEALTH SYSTEM & PAYER RELATIONSHIPS INFORMATION TECHNOLOGY SUPPORT 90% Cologuard of 21K unscreened people auto ordered for cancelled or being ordered a Cologuard no-show colonoscopies EXACT SCIENCES Source: Exact Sciences internal data 89
Slide 90: Sizzle reel video
SURROUND SOUND MARKETING Sizzle reel video EXACT SCIENCES 90 90
Slide 91: 10B+ advertisement impressions each year
SURROUND SOUND MARKETING TRADITIONAL VIDEO SOCIAL 10B+ advertisement impressions each year VIDEO STREAMING SEARCH RADIO HCP CHANNELS Source: Exact Sciences internal data EXACT SCIENCES 91
Slide 92: Optimizing spend as revenue grows
Optimizing spend as revenue grows Total revenue Sales & marketing expense $2.40B $2.08B $1.77B $1.49B $876M 63% 50% 49% 41% 35% Low $454M 40% 30’s 52% $266M 44% 44% $99M 55% 55% 114% 112% 58% 58% 2016 2017 2018 2019 2020 2021 2022 2023E EXACT SCIENCES 2023E is midpoint of Exact Sciences guidance pro
Slide 93: Provide seamless experience
Provide seamless experience Everett Cunningham Chief Commercial Officer EXACT SCIENCES 93
Slide 94: Invest in world-class talent dedicated to fighting cancer
Invest in world-class talent dedicated to fighting cancer Drive profitable Offer tests that revenue impact decision-making Provide a seamless Generate experience for rock-solid clinical customers evidence Increase access & drive adoption EXACT SCIENCES 94
Slide 95: We don't just have great tests, we offer great services
We don’t just have great tests, we offer great services EXACT SCIENCES 95
Slide 96: 15M+ patient calls each year
15M+ 75%+ patient calls enabled each year by technology EXACT SCIENCES 96 Source: Exact Sciences internal data
Slide 97: Investing in a seamless customer experience
Investing in a seamless customer experience Customer experience Customer support team Test volume $131M $113M $87M $62M Source: Exact Sciences internal data EXACT SCIENCES 97 2020 2021 2022 2023E
Slide 98: We have been working to perfect the customer experience for nearly a decade
We have been working to perfect the customer experience for nearly a decade 220+ experiments conducted EXACT SCIENCES Source: Exact Sciences internal data 98
Slide 99: Cologuard kit return app improving ease of use
Cologuard kit return “app” improving ease of use doubled completion rate of schedule UPS pickup feature 3 min 30 seconds amount of time to complete task 8 min 5.5 min total app time Source: Exact Sciences internal data EXACT SCIENCES 99
Slide 100: Challenges in cancer care
Challenges in cancer care Waiting for answers until follow-up visit; anxious about having cancer Unaware/unsure of Overwhelmed by Overwhelmed by tumor profiling Difficult to keep track of screening tests Anxious for results; test diagnosis – don’t know info – don’t know where to get when next test/
Slide 101: Challenges in cancer care
Challenges in cancer care Telehealth tool provides convenient access to provider for questions Track sample throughout process; know when result is ready Receive reminders and Digital tool shows Waiting for answers until Diagnosis details links to re-order tests, provider and patient they follow-up
Slide 102: Drive profitable revenue
Drive profitable revenue Jeff Elliott Chief Financial Officer EXACTSCIENCES EXACT SCIENCES 102
Slide 103: Invest in world-class talent dedicated to fighting cancer
Invest in world-class talent dedicated to fighting cancer Drive profitable Offer tests that revenue impact decision-making Provide a seamless Generate experience for rock-solid clinical customers evidence Increase access & drive adoption EXACT SCIENCES 103
Slide 104: Grow the core business, increase profits, allocate capital
Grow the Increase profits Allocate core business and cash flow capital EXACTSCIENCES EXACT SCIENCES 104
Slide 105: Q1 was a record-breaking quarter
GROW THE CORE BUSINESS Q1 was a record-breaking quarter Core revenue Non-GAAP gross margin Adjusted EBITDA Free cash flow +33% +1.7 pts +$136M +$140M $598M 74.0% $450M 72.3% $46M ($68M) ($90M) ($207M) 1Q22 1Q23 1Q22 1Q23 1Q22 1Q23 1Q22 1Q23 Please refer to the appendix accompanying this presentation
Slide 106: Financial targets
GROW THE CORE BUSINESS FINANCIAL TARGETS ~15% 20%+ compounded annual adjusted EBITDA revenue growth 2022-2027 margin in 2027 (excluding COVID and prostate) Note: compounded annual revenue growth based on total revenue in 2022, excluding revenue generated from COVID-19 testing and the divested Oncoty
Slide 107: Screening revenue
GROW THE CORE BUSINESS Screening revenue 8-year CAGR: 60%+ $1.78B Growth drivers $1.42B Rescreens $1.06B 45-49 age group $810M $815M Commercial productivity $454M $266M Health system connections $99M $39M 2015 2016 2017 2018 2019 2020 2021 2022 2023E CAGR revenue calculated using GAAP figures; 2023E
Slide 108: Precision Oncology revenue
GROW THE CORE BUSINESS Precision Oncology revenue 5-year CAGR: 9% $613M Growth drivers $601M $562M International expansion $456M $440M $394M Node-positive adoption Therapy selection Biopharma partnerships 2018 2019 2020 2021 2022 2023E CAGR revenue calculated using GAAP figures; 2023E is midpoint of
Slide 109: Non-GAAP gross profit
GROW THE CORE BUSINESS Non-GAAP gross profit 8-year CAGR: 80%+ $1.75B 73%+ $1.51B Key drivers Non-GAAP gross margin $1.31B Volume leverage $1.14B Automation projects $660M Rescreen mix increasing $338M $188M Next-generation Cologuard $15M $54M 2015 2016 2017 2018 2019 2020 2021 2022 2023E 2023E is m
Slide 110: Adjusted EBITDA grew $136M Y/Y
INCREASE PROFITS & CASH FLOW Adjusted EBITDA Expect adjusted EBITDA margin grew $136M Y/Y to increase 15 pts by 2027 $46M 2023 guidance 2027 target $5M ($13M) 5% 20%+ ($46M) ($90M) 1Q22 2Q22 3Q22 4Q22 1Q23 2023 guidance for adjusted EBITDA margin refers to midpoint of guidance provided on May 9, 202
Slide 111: Rescreen eligibility and compliance
INCREASE PROFITS & CASH FLOW Eligible for second rescreen Eligible for first rescreen ~30 pt 0.4M 0.3M higher compliance for 2nd rescreen 0.1M ~20 pt 2.0M 1.7M 1.3M 1.3M 0.8M higher compliance for 1st rescreen 2021 2022 2023E 2024E 2025E Source: Exact Sciences internal data based on 90-day adherence
Slide 112: Free cash flow
INCREASE PROFITS & CASH FLOW Free cash flow Positive ($21M) ($68M) ($86M) ($124M) 2Q22 3Q22 4Q22 1Q23 2Q23E Please refer to the appendix accompanying this presentation for discussion of non-GAAP financial measures and reconciliations to GAAP financial measures EXACTSCIENCES EXACT SCIENCES 112
Slide 113: Disciplined capital allocation
ALLOCATE CAPITAL Core Pipeline Retaining business opportunities cash flow Disciplined capital allocation EXACTSCIENCES EXACT SCIENCES 113
Slide 114: 20-day decrease in DSOs
ALLOCATE CAPITAL 50 20-day 35K 99% decrease in decrease in DSOs Cologuard claim errors 30K 45 25K 40 20K 35 15K 30 10K 25 5K 20 0K Jan 22 Mar 22 May 22 Jul 22 Sep 22 Nov 22 Jan 23 Mar 23 Jan 22 Mar 22 May 22 Jul 22 Sep 22 Nov 22 Jan 23 Mar 23 Source: Exact Sciences internal data EXACTSCIENCES EXACT
Slide 115: Enhancing our state-of-the-art labs
ALLOCATE CAPITAL Enhancing our state-of-the-art labs $200M cumulative cost savings expected by 2030 EXACTSCIENCES EXACT SCIENCES 115
Slide 116: Market size and penetration
ALLOCATE CAPITAL Market size ($) MCED $25B CRC MRD $18B $15B Therapy selection Liver Hereditary cancer testing Pancreatic Lung Breast Rare disease Thyroid Esophageal 0% 20% 40% 60% 80% 100% Total market penetration Source: U.S. Census data and Exact Sciences estimates; U.S. markets only EXACT SCIENC
Slide 117: Incremental revenue growth and non-GAAP gross profit vs Dx group
~7x incremental ~8x non-GAAP gross revenue growth profit dollars $316M $1.75B $44M $230M 1 2 1 2 Dx group Dx group average average Source: Exact Sciences guidance provided May 9, 2023; FactSet Dx group includes 23andMe, Adaptive, GeneDX, Guardant Health, Invitae, Myriad, Natera, NeoGenomics, Persona
Slide 118: Expert health care professional panel
Expert health care professional panel Seth A. Gross Lisa Ravindra Ronan J. Kelly Charles Geyer MD, FACG, FASGE, AGAF MD, FACP MD, MBA MD, FACP Professor of Medicine Assistant Professor of Medicine, Director of the Charles A. Sammons Cancer Center, Chief Scientific Officer, Clinical Chief, Division o
Slide 119: EXACT SCIENCES
EXACTSCIENCES EXACT SCIENCES 119 119
Slide 120: Exact Sciences is a powerful innovator and growth engine
Exact Sciences is a powerful innovator and growth engine our team powers best-in-class profitable growth our flywheel scientific capabilities for years to come EXACT SCIENCES 120
Slide 121: We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment
We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment. EXACT SCIENCES SCIENCES 121 EXACT
Slide 122: Appendix: Non-GAAP disclosure
Appendix Non-GAAP disclosure In addition to the company's financial results determined in accordance with U.S. GAAP, the company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. The company presents EBITDA, adjusted EBITDA, non-GAAP gr
Slide 123: EBITDA and Adjusted EBITDA Reconciliations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) (In thousands) 1Q22 2Q22 3Q22 4Q22 1Q23 Net loss $ (180,937) $ (166,063) $ (148,761) $ (127,745) $ (74,151) Interest expense (income) (1) 4,478 4,511 5,235 5,410 (4,1
Slide 124: Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations (Amounts in thousands) 1Q23 1Q22 Revenue $ 602,450 $ 486,571 Cost of sales (exclusive of amortization of acquired intangible assets) 156,866 134,705 Amortization of acq
Slide 125: Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations (Amounts in thousands) For the Year Ended 2015 2016 2017 2018 2019 2020 2021 2022 Revenue $ 39,437 $ 99,376 $ 265,989 $ 454,462 $ 876,293 $ 1,491,391 $ 1,767,087 $ 2,08
Slide 126: Reconciliation of Core Revenue
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of Core Revenue (Amounts in thousands) GAAP 1Q23 1Q22 % Change Screening $ 443,195 $ 306,522 45 % Precision Oncology 155,432 152,620 2 % COVID-19 Testing 3,823 27,429 (86) % Total $ 602,450 $ 486,571 24 % Non-GAAP For
Slide 127: Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow (Amounts in thousands) 1Q22 2Q22 3Q22 4Q22 1Q23 Net cash provided by (used in) operating activities $ (173,754) $ (60,916) $ (40,926) $ 52,037 $ (3